Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurochem is to conduct an 18-month open-label extension study for its ongoing North American phase III clinical trial for Alzhemed, its investigational product candidate for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
All patients who complete the phase III clinical trial will be offered the opportunity to receive Alzhemed in the extension study, to be initiated in the second quarter of 2006.
Neurochem is currently conducting a 18-month phase III clinical trial in 1,052 mild-to-moderate Alzheimer’s disease (AD) patients, which is being carried out at close to 70 sites across the US and Canada. To date, 338 patients have already completed 12 months on study medication and the trial is now scheduled to be completed by January 2007.
“Alzhemed has shown promising results in clinical trials as a drug that may favorably influence the disease process. Furthermore, our experience with patients receiving Alzhemed for up to 20 months in an open-label phase II extension study has been encouraging. Millions of patients would stand to gain if the results of Neurochem’s phase III trials are positive,” said Dr Paul Aisen, professor of neurology and medicine, Georgetown University Medical Center in Washington DC.